IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1369 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1433    
    Printed80    
    Emailed0    
    PDF Downloaded85    
    Comments [Add]    

Recommend this journal

 

 RESEARCH PAPER
Year : 1999  |  Volume : 31  |  Issue : 2  |  Page : 116-119

A study on the characteristics of Ca2+ channels in vas deferens isolated from cyclophosphamide treated rats



Correspondence Address:
Reddy A Gopala


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objectives: To study the functional characteristics of ca2+ channels in rat vas deferens following cyclophosphamide treatment. Methods: The study was conducted on vas deferens isolated from cyclophosphamide-treated (40 mg/kg s.c., once on alternate day for 5 times) albino rats. The following parameters were assessed: IC50 values of verapamil against 1 m mol BaCl 2 -induced rhythmic contractions, maximum absolute tension (g) generated by norepinephrine (NE) in the presence of verapamil 10-6 mol and EC 50 value of NE in inducing contractile responses in the presence of verapamil 10-6 mol. Results: The mean IC50 value of verapamil against BaCl2 -induced rhythmic contractions was significantly decreased, the maximum absolute tension generated by NE did not change significantly and the EC50 value of NE in the presence of verapamil was significantly increased in the cyclophosphamide-treated group as compared to the control. Conclusion: The study revealed decreased functional activity of Ca2+ channels of rat vas deferens following cyclophosphamide treatment.






[PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow